Skip to main content
. 2017 Nov 21;18:194. doi: 10.1186/s12931-017-0678-7

Table 1.

Clinical characteristics of study subjects

Healthy Non-severe Asthma Severe Asthma
Number 12 9 13
Age, years 39.8 ± 2.5 52.6 ± 4.2 54.4 ± 3.8*
Gender, Female/Male 6/6 7/2 11/2
Inhaled corticosteroid dose, μg BDP equivalent 0 150.0 ± 105.2 2000 ± 258.2**##
Atopy (n) 5 4 5
Receiving oral corticosteroids 0 0 4
Pre-bronchodilator FEV1 (L) 3.4 ± 0.2 2.2 ± 0.3 1.5 ± 0.2***
Pre-bronchodilator FEV1 of predicted value (%) 94.9 ± 2.5 82.3 ± 5.5 61.0 ± 5.5***
FEV1/FVC (%) 88.2 ± 2.3 69.5 ± 2.0 64.5 ± 3.1***

Data are expressed as mean ± SEM

BDP beclomethasone dipropionate, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity

* p < 0.05, *** p < 0.001 compared to healthy subjects. ## p < 0.01 compared to patients with non-severe asthma